Literature DB >> 19179445

Mechanisms of resistance to structurally diverse antiestrogens differ under premenopausal and postmenopausal conditions: evidence from in vitro breast cancer cell models.

Ping Fan1, Wei Yue, Ji-Ping Wang, Sarah Aiyar, Yan Li, Tae-Hyun Kim, Richard J Santen.   

Abstract

This study questioned whether the mechanisms of resistance to antiestrogens differ when acquired under premenopausal (Pre-M) vs. postmenopausal (PM) conditions and whether structurally diverse antiestrogens induce adaptation of differing signaling pathways. To address this issue, we conducted systematic studies under Pre-M vs. PM culture conditions with long-term exposure to different antiestrogens and examined the resultant "specific biologic signatures" of the various resistant cells. Estradiol stimulated growth and inhibited apoptosis of "pre-menopausal" antiestrogen-resistant cells but exerted opposite effects on their "post-menopausal" counterparts. Under Pre-M conditions, tamoxifen (TAM)-resistant cells exhibited a marked translocation of estrogen receptor alpha from the nucleus into the cytoplasm, whereas this occurred to a lesser extent under PM conditions. MCF-7 cells exposed to PM but not Pre-M conditions exhibited up-regulation of basal epidermal growth factor (EGF) receptor (EGFR) levels, an effect exaggerated in cells exposed to 4-hydroxytamoxifen. Differing effects occurred in response to structurally divergent antiestrogens. Long-term treatment with both 4-hydroxytamoxifen and ICI182,780 increased EGFR levels, but this was not seen in response to TAM. Surprisingly, EGF administration slightly increased cell number in TAM-resistant cells, whereas only increasing cell weight and decreasing cell number in EGFR overexpressing-resistant cells. To assess potential differences among various parental cell lines, we induced resistance in cell lines obtained from other laboratories and confirmed the results from our own parental cells with minor differences. Together, these data demonstrate that culture of breast cancer cells under Pre-M and PM conditions and structurally diverse antiestrogens results in adaptive responses with differing biological signatures.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19179445      PMCID: PMC2671908          DOI: 10.1210/en.2008-1195

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  44 in total

1.  Acquired antiestrogen resistance in MCF-7 human breast cancer sublines is not accomplished by altered expression of receptors in the ErbB-family.

Authors:  S S Larsen; M Egeblad; M Jäättelä; A E Lykkesfeldt
Journal:  Breast Cancer Res Treat       Date:  1999-11       Impact factor: 4.872

2.  Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17beta-estradiol.

Authors:  R X Song; G Mor; F Naftolin; R A McPherson; J Song; Z Zhang; W Yue; J Wang; R J Santen
Journal:  J Natl Cancer Inst       Date:  2001-11-21       Impact factor: 13.506

3.  Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex).

Authors:  R A McClelland; D Barrow; T A Madden; C M Dutkowski; J Pamment; J M Knowlden; J M Gee; R I Nicholson
Journal:  Endocrinology       Date:  2001-07       Impact factor: 4.736

4.  Comparative analyses of mechanistic differences among antiestrogens.

Authors:  A L Wijayaratne; S C Nagel; L A Paige; D J Christensen; J D Norris; D M Fowlkes; D P McDonnell
Journal:  Endocrinology       Date:  1999-12       Impact factor: 4.736

5.  Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells.

Authors:  Janice M Knowlden; Iain R Hutcheson; Helen E Jones; Tracieann Madden; Julia M W Gee; Maureen E Harper; Denise Barrow; Alan E Wakeling; Robert I Nicholson
Journal:  Endocrinology       Date:  2003-03       Impact factor: 4.736

6.  The potential role of estrogen in aromatase regulation in the breast.

Authors:  W Yue; L M Berstein; J P Wang; G M Clark; C J Hamilton; L M Demers; R J Santen
Journal:  J Steroid Biochem Mol Biol       Date:  2001-12       Impact factor: 4.292

7.  Estrogen regulates Ah responsiveness in MCF-7 breast cancer cells.

Authors:  David C Spink; Barbara H Katz; Mirza M Hussain; Brian T Pentecost; Zhimin Cao; Barbara C Spink
Journal:  Carcinogenesis       Date:  2003-09-11       Impact factor: 4.944

8.  Local uptake and synthesis of oestrone in normal and malignant postmenopausal breast tissues.

Authors:  A A Larionov; L M Berstein; W R Miller
Journal:  J Steroid Biochem Mol Biol       Date:  2002-05       Impact factor: 4.292

9.  Tamoxifen resistance by a conformational arrest of the estrogen receptor alpha after PKA activation in breast cancer.

Authors:  Rob Michalides; Alexander Griekspoor; Astrid Balkenende; Desiree Verwoerd; Lennert Janssen; Kees Jalink; Arno Floore; Arno Velds; Laura van't Veer; Jacques Neefjes
Journal:  Cancer Cell       Date:  2004-06       Impact factor: 31.743

10.  Activation of the MAPK pathway enhances sensitivity of MCF-7 breast cancer cells to the mitogenic effect of estradiol.

Authors:  Wei Yue; Ji-Ping Wang; Mark Conaway; Shigeru Masamura; Yuebai Li; Richard J Santen
Journal:  Endocrinology       Date:  2002-09       Impact factor: 4.736

View more
  16 in total

1.  GPER functions as a tumor suppressor in triple-negative breast cancer cells.

Authors:  Christine Weißenborn; Tanja Ignatov; Hans-Joachim Ochel; Serban Dan Costa; Ana Claudia Zenclussen; Zoya Ignatova; Atanas Ignatov
Journal:  J Cancer Res Clin Oncol       Date:  2014-02-20       Impact factor: 4.553

Review 2.  EGFR signaling in breast cancer: bad to the bone.

Authors:  John Foley; Nicole K Nickerson; Seungyoon Nam; Kah Tan Allen; Jennifer L Gilmore; Kenneth P Nephew; David J Riese
Journal:  Semin Cell Dev Biol       Date:  2010-09-09       Impact factor: 7.727

3.  Analysis of factors affecting endocrine therapy resistance in breast cancer.

Authors:  Min Zhang; Hui Chen; Jun Gu
Journal:  Oncol Lett       Date:  2015-11-06       Impact factor: 2.967

4.  Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer.

Authors:  Chellappagounder Thangavel; Jeffry L Dean; Adam Ertel; Karen E Knudsen; C Marcelo Aldaz; Agnieszka K Witkiewicz; Robert Clarke; Erik S Knudsen
Journal:  Endocr Relat Cancer       Date:  2011-04-28       Impact factor: 5.678

5.  Progesterone receptor action: defining a role in breast cancer.

Authors:  Andrea R Daniel; Christy R Hagan; Carol A Lange
Journal:  Expert Rev Endocrinol Metab       Date:  2011-05-01

6.  Estrogen receptor alpha 46 is reduced in tamoxifen resistant breast cancer cells and re-expression inhibits cell proliferation and estrogen receptor alpha 66-regulated target gene transcription.

Authors:  Carolyn M Klinge; Krista A Riggs; Nalinie S Wickramasinghe; Celia G Emberts; David B McConda; Parul N Barry; Joan E Magnusen
Journal:  Mol Cell Endocrinol       Date:  2010-03-17       Impact factor: 4.102

Review 7.  Dissecting the Roles of PDCD4 in Breast Cancer.

Authors:  Qian Cai; Hsin-Sheng Yang; Yi-Chen Li; Jiang Zhu
Journal:  Front Oncol       Date:  2022-06-20       Impact factor: 5.738

8.  c-Src modulates estrogen-induced stress and apoptosis in estrogen-deprived breast cancer cells.

Authors:  Ping Fan; Obi L Griffith; Fadeke A Agboke; Pavana Anur; Xiaojun Zou; Russell E McDaniel; Karen Creswell; Sung Hoon Kim; John A Katzenellenbogen; Joe W Gray; V Craig Jordan
Journal:  Cancer Res       Date:  2013-05-23       Impact factor: 12.701

9.  Proteomic analysis of acquired tamoxifen resistance in MCF-7 cells reveals expression signatures associated with enhanced migration.

Authors:  Changhua Zhou; Qiu Zhong; Lyndsay V Rhodes; Ian Townley; Melyssa R Bratton; Qiang Zhang; Elizabeth C Martin; Steven Elliott; Bridgette M Collins-Burow; Matthew E Burow; Guangdi Wang
Journal:  Breast Cancer Res       Date:  2012-03-14       Impact factor: 6.466

10.  Loss of pigment epithelium-derived factor: a novel mechanism for the development of endocrine resistance in breast cancer.

Authors:  Rifat Jan; Min Huang; Joan Lewis-Wambi
Journal:  Breast Cancer Res       Date:  2012-11-14       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.